Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Enanta Pharmaceuticals Inc
Cash from Financing Activities
Enanta Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
|
Cash from Financing Activities
$190.5m
|
CAGR 3-Years
186%
|
CAGR 5-Years
106%
|
CAGR 10-Years
13%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Enanta Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
190.5m
USD
Based on the financial report for Dec 31, 2023, Enanta Pharmaceuticals Inc's Cash from Financing Activities amounts to 190.5m USD.
What is Enanta Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
13%
Over the last year, the Cash from Financing Activities growth was 1 680%. The average annual Cash from Financing Activities growth rates for Enanta Pharmaceuticals Inc have been 186% over the past three years , 106% over the past five years , and 13% over the past ten years .